[1] |
Tallab TM. Richner⁃Hanhart syndrome: importance of early diagnosis and early intervention[J]. J Am Acad Dermatol, 1996,35(5 Pt 2):857⁃859. doi: 10.1016/S0190⁃9622(96)90104⁃8.<br />
|
[2] |
al⁃Hemidan AI, al⁃Hazzaa SA. Richner⁃Hanhart syndrome (tyrosinemia type II). Case report and literature review[J]. Ophthalmic Genet, 1995,16(1):21⁃26. doi: 10.3109/13816819509057850.<br />
|
[3] |
Bouyacoub Y, Zribi H, Azzouz H, et al. Novel and recurrent mutations in the TAT gene in Tunisian families affected with Richner⁃Hanhart syndrome[J]. Gene, 2013,529(1):45⁃49. doi: 10.1016/j.gene.2013.07.066.<br />
|
[4] |
Ellaway CJ, Holme E, Standing S, et al. Outcome of tyrosinaemia type III[J]. J Inherit Metab Dis, 2001,24(8):824⁃832. doi: 10.1023/A:1013936107064.<br />
|
[5] |
Scott CR. The genetic tyrosinemias[J]. Am J Med Genet C Semin Med Genet, 2006,142C(2):121⁃126. doi: 10.1002/ajmg.c. 30092.<br />
|
[6] |
Kocabeyoglu S, Mocan MC, Irkec M. In vivo confocal microscopic features of corneal pseudodendritic lesions in tyrosinemia type II[J]. Cornea, 2014,33(10):1106⁃1108. doi: 10.1097/ICO. 0000000000000226.<br />
|
[7] |
Madan V, Gupta U. Tyrosinaemia type II with diffuse plantar keratoderma and self⁃mutilation[J]. Clin Exp Dermatol, 2006,31(1):54⁃56. doi: 10.1111/j.1365⁃2230.2005.01946.x.<br />
|
[8] |
Rabinowitz LG, Williams LR, Anderson CE, et al. Painful keratoderma and photophobia: hallmarks of tyrosinemia type II[J]. J Pediatr, 1995,126(2):266⁃269. doi: 10.1016/S0022⁃3476(95)70558⁃9.<br />
|
[9] |
Sener RN. Tyrosinemia: computed tomography, magnetic reso⁃nance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain[J]. J Comput Assist Tomogr, 2005,29(3):323⁃325. doi: 10.1097/01.rct.0000163179.10595.c4.<br />
|
[10] |
Holme E1, Lindstedt S. Tyrosinaemia type I and NTBC (2⁃(2⁃nitro⁃4⁃trifluoromethylbenzoyl)⁃1,3⁃cyclohexanedione)[J]. J Inherit Metab Dis, 1998,21(5):507⁃517. doi: 10.1023/A:1005410820201.<br />
|
[11] |
Schauwvlieghe PP, Jaeken J, Kestelyn P, et al. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC[J]. Cornea, 2013,32(1):91⁃94. doi: 10.1097/ICO.0b013e318243e474.<br />
|
[12] |
Thimm E, Richter⁃Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long⁃term treatment with NTBC[J]. J Inherit Metab Dis, 2012,35(2):263⁃268. doi: 10.1007/s10545⁃011⁃9394⁃5.<br />
|
[13] |
de Andrade RB, Gemelli T, Rojas DB, et al. Tyrosine inhibits creatine kinase activity in cerebral cortex of young rats[J]. Metab Brain Dis, 2011,26(3):221⁃227. doi: 10.1007/s11011⁃011⁃9255⁃9.<br />
|
[14] |
Ferreira GK, Carvalho⁃Silva M, Gonçalves CL, et al. L⁃tyrosine administration increases acetylcholinesterase activity in rats[J]. Neurochem Int, 2012,61(8):1370⁃1374. doi: 10.1016/j.neuint. 2012.09.017.<br />
|
[15] |
Culic V, Betz RC, Refke M, et al. Tyrosinemia type II (Richner⁃Hanhart syndrome):a new mutation in the TAT gene[J]. Eur J Med Genet, 2011,54(3):205⁃208. doi: 10.1016/j.ejmg.2010.11. 013.<br />
|
[16] |
Gewin V. Medicine: expanding possibilities[J]. Nature, 2015,528(7580):S10⁃11. doi: 10.1038/528S10a.<br />
|